View Exam | PowerPak

1. All of the following are characteristics of the pathophysiology of type 2 diabetes EXCEPT:

A. Insulin resistance in peripheral tissues B. Beta-cell dysfunction C. Autoimmune destruction of beta-cells D. Increased glucagon release

2. According to the American Association of Clinical Endocrinologist guidelines, if hemoglobin A1c levels remain above goal after 3 months of treatment with metformin, the BEST agent to add next is:

A. Liraglutide, a glucagon-like peptide-1 receptor agonist B. Pioglitazone, a thiazolidinedione C. Glargine, a long-acting basal insulin D. Glipizide, a sulfonylurea

3. All of the following agents significantly affect postprandial glucose excursions EXCEPT:

A. Insulin lispro B. Liraglutide C. Metformin D. Repaglinide

4. Which of the following is NOT true regarding glucagon-like peptide-1 receptor agonists?

A. They can cause significant nausea in up to 40% of patients B. All of the agents must be administered 60 minutes prior to a meal for optimum effect C. They work, in part, by increasing satiety, decreasing gastric emptying, and decreasing food intake D. They are injected subcutaneously into the abdomen, thigh, or upper arm

5. Which pair correctly matches the glucagon-like peptide-1 receptor agonist to its recommended dosing schedule?

A. Liraglutide: once weekly B. Albiglutide: once daily C. Exenatide: once weekly or twice daily, depending on the formulation D. Dulaglutide: twice weekly

6. Which glucagon-like peptide-1 receptor agonist must be reconstituted before administration?

A. Exenatide twice daily B. Albiglutide C. Dulaglutide D. Liraglutide

7. Which of the glucagon-like peptide-1 receptor agonists should be avoided in patients with a creatinine clearance lower than 30 mL/min?

A. Dulaglutide B. Albiglutide C. Exenatide D. Liraglutide

8. Which glucagon-like peptide-1 receptor agonist has been compared to preprandial insulin in head-to-head trials?

A. Lixisenatide B. Exenatide C. Albiglutide D. All of the above

9. Which of the following is/are an advantage(s) of adding a glucagon-like peptide-1 receptor agonist to insulin?

A. Decreased insulin requirements B. Less hypoglycemia C. Weight loss D. All of the above

10. Which of the following patients would be the best candidate for the addition of a glucagon-like peptide-1 receptor agonist?

A. A 17-year-old male with type 1 diabetes and uncontrolled postprandial glucose B. A 42-year-old female who is normal weight and newly diagnosed with type 2 diabetes C. An overweight 53-year-old man on metformin with type 2 diabetes and uncontrolled postprandial glucose D. An overweight 62-year-old female with type 2 diabetes on 10 units daily of insulin glargine and uncontrolled fasting blood sugar

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. All of the following are characteristics of the pathophysiology of type 2 diabetes EXCEPT:

2. According to the American Association of Clinical Endocrinologist guidelines, if hemoglobin A1c levels remain above goal after 3 months of treatment with metformin, the BEST agent to add next is:

3. All of the following agents significantly affect postprandial glucose excursions EXCEPT:

4. Which of the following is NOT true regarding glucagon-like peptide-1 receptor agonists?

5. Which pair correctly matches the glucagon-like peptide-1 receptor agonist to its recommended dosing schedule?

6. Which glucagon-like peptide-1 receptor agonist must be reconstituted before administration?

7. Which of the glucagon-like peptide-1 receptor agonists should be avoided in patients with a creatinine clearance lower than 30 mL/min?

8. Which glucagon-like peptide-1 receptor agonist has been compared to preprandial insulin in head-to-head trials?

9. Which of the following is/are an advantage(s) of adding a glucagon-like peptide-1 receptor agonist to insulin?

10. Which of the following patients would be the best candidate for the addition of a glucagon-like peptide-1 receptor agonist?

« Return to Activity

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

The shopping cart is empty

Customers who Purchasedthis Activity also Purchased

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. All of the following are characteristics of the pathophysiology of type 2 diabetes EXCEPT:

2. According to the American Association of Clinical Endocrinologist guidelines, if hemoglobin A1c levels remain above goal after 3 months of treatment with metformin, the BEST agent to add next is:

3. All of the following agents significantly affect postprandial glucose excursions EXCEPT:

4. Which of the following is NOT true regarding glucagon-like peptide-1 receptor agonists?

5. Which pair correctly matches the glucagon-like peptide-1 receptor agonist to its recommended dosing schedule?

6. Which glucagon-like peptide-1 receptor agonist must be reconstituted before administration?

7. Which of the glucagon-like peptide-1 receptor agonists should be avoided in patients with a creatinine clearance lower than 30 mL/min?

8. Which glucagon-like peptide-1 receptor agonist has been compared to preprandial insulin in head-to-head trials?

9. Which of the following is/are an advantage(s) of adding a glucagon-like peptide-1 receptor agonist to insulin?

10. Which of the following patients would be the best candidate for the addition of a glucagon-like peptide-1 receptor agonist?

« Return to Activity

Customers who Purchased
this Activity also Purchased